Results 251 to 260 of about 26,327 (353)

Efficacy of luseogliflozin for renal function preservation in patients with type 2 diabetes mellitus and impaired renal function: A randomized open‐label clinical trial (RESOLUTION study)

Journal of Diabetes Investigation, EarlyView.
Luseogliflozin alleviated renal function decline (eGFR) after an initial decrease, showing renoprotective effects in patients with renal impairment. Luseogliflozin did not increase renal events, showing safety even in patients with moderate‐to‐severe renal impairment.
Munehiro Kitada, Masao Toyoda, Osamu Sekine, Daisuke Suzuki, Yosuke Okada, Yoshikata Morita, Hideki Nishimura, Hiroaki Satoh, Hideki Kamiya, Toshinari Takamura, Motohide Isono, Takeshi Onoue, Hiroshi Arima, Kenichi Tanaka, Masaji Miyamoto, Yasushi Omura, Daisuke Yabe, Takehiro Kato, Akimichi Asano, Yutaka Wakasa, Satoshi Miyamoto, Shinji Kume, Tomohiko Ito, Shin‐ichi Araki, Atsushi Nakagawa, RESOLUTION Study Investigators   +25 more
wiley   +1 more source

Evaluation of prescribing adherence to guideline-directed medical therapy in patients with chronic heart failure: a retrospective study at the National Heart Centre in Oman. [PDF]

BMC Cardiovasc Disord
Albalushi MA, Neshat-Mokadem L, Al-Mawaali G.   +2 more
europepmc   +1 more source

Effects of hypertension and anti-hypertensive treatment on Aβ plaque load, Aβ–synthesising and –degrading enzymes in frontal cortex [PDF]

, 2016
Ashby, Emma L, Kehoe, Patrick Gavin, Love, Seth, Miners, J S   +3 more
core   +1 more source

Colchicine and the risk of major adverse cardiovascular events in patients with gout and Type 2 diabetes: A nationwide cohort study

Journal of Internal Medicine, EarlyView.
Abstract Background Type 2 diabetes mellitus (T2DM) and gout are associated with an increased risk of cardiovascular events. Despite the approval for the secondary prevention of cardiovascular diseases by the United States Food and Drug Administration in 2023, evidence regarding the effectiveness of colchicine among T2DM population remains limited ...
Minjeong Jeon, Yongtai Cho, Sungho Bea, Wonkyoung You, Sung Kweon Cho, Seungho Ryu, Yoosoo Chang, Ju‐Young Shin   +7 more
wiley   +1 more source

Comparative renal effects of angiotensin receptor neprilysin inhibitors and ACEi/ARB: a systematic review and meta-analysis. [PDF]

Clin Kidney J
Covic A, Voroneanu L, Stefan AE, Brinza C, Covic A, Kanbay M, Scripcariu V, Iliescu S, Burlacu A.   +8 more
europepmc   +1 more source

Establishment of a mouse model for ischaemic heart failure induced by coronary microembolization via left ventricular oil injection

Experimental Physiology, EarlyView.
Abstract Over the past three decades, there has been a steady increase in clinical attention to ischaemic heart failure caused by coronary microembolization. Nonetheless, a suitable mouse model for studying this condition remains limited. In the present study, we developed a mouse model of coronary microembolization‐induced ischaemic heart failure by ...
Lang Pei, Yusheng Hong, Qiuyue Wu, Jianyi Lv, Changlong Li, Xueyun Huo, Xin Liu, Di Zhang, Meng Guo, Zhenwen Chen, Xiaoyan Du   +10 more
wiley   +1 more source

Angiotensin Receptor Neprilysin Inhibitors for Hypertension and Proteinuria Management During Atezolizumab/Bevacizumab Treatment for Hepatocellular Carcinoma. [PDF]

Cancer Diagn Progn
Ishikawa T, Sato R, Natsui H, Iwasawa T, Ogawa M, Kobayashi Y, Sato T, Yokoyama J, Honma T.   +8 more
europepmc   +1 more source

Race and Ethnicity in Heart Failure Trials: Time to Update Recommended Categories for Global Relevance. [PDF]

J Am Heart Assoc
Yang M, Kondo T, Dewan P, Desai AS, Sibulo AS, Lam CSP, Chiang CE, Gomez EA, Martinez FA, Thierer J, Nicolau JC, Kerr Saraiva JF, Kitakaze M, Packer M, Vaduganathan M, Vinh PN, Abraham WT, Jhund PS, Solomon SD, McMurray JJV.   +19 more
europepmc   +1 more source

Angiotensin Receptor-Neprilysin Inhibition in Heart Failure With Reduced Ejection Fraction

, 2016
Marvin A. Konstam
openalex   +1 more source

Aryl Hydrocarbon Receptor in Health and Disease

MedComm, Volume 6, Issue 11, November 2025.
Based on the structure and ligands of AhR, this review introduces the AhR‐related signaling pathways and their roles in health and diseases. Agonists and antagonists of AhR as well as new strategies for treatment using the microbial–AhR axis are summarized. A prospect was made for the future use of AhR as a therapeutic target.
Haonan Li, Yufeng Fan, Jizheng Liu, Shumin Dong, Bin Wen, Yunfei Zhang, Xiaocui Wang, Xuemei Duan, Ying Hu, Ze Yan, Huifeng Shang, Yukai Jing   +11 more
wiley   +1 more source